Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
& Groisman, E
378 Amivantamab, a bispecific antibody targeting EGFR and MET, addresses the limitations of monotargeted inhibitors and is approved for advanced or metastatic NSCLC with EGFR exon 20 insertions
Sin embargo, es importante seguir los protocolos adecuados y consultar con profesionales sanitarios
| All Rights Reserved
US$ 25.63
US$ 23.59
US$ 25.51
US$ 27.17
US$ 22.45
US$ 27.08
US$ 28.24
US$ 22.59
